147 related articles for article (PubMed ID: 16148409)
1. Differential expression of MART-1, tyrosinase, and SM5-1 in primary and metastatic melanoma.
Reinke S; Königer P; Herberth G; Audring H; Wang H; Ma J; Guo Y; Sterry W; Trefzer U
Am J Dermatopathol; 2005 Oct; 27(5):401-6. PubMed ID: 16148409
[TBL] [Abstract][Full Text] [Related]
2. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
Clarkson KS; Sturdgess IC; Molyneux AJ
J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
[TBL] [Abstract][Full Text] [Related]
3. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
[TBL] [Abstract][Full Text] [Related]
4. SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions.
Trefzer U; Rietz N; Chen Y; Audring H; Herberth G; Siegel P; Reinke S; Königer P; Wu S; Ma J; Liu Y; Wang H; Sterry W; Guo Y
Arch Dermatol Res; 2000 Dec; 292(12):583-9. PubMed ID: 11214818
[TBL] [Abstract][Full Text] [Related]
5. Expression of melanocytic differentiation markers in malignant melanomas of the oral and sinonasal mucosa.
Prasad ML; Jungbluth AA; Iversen K; Huvos AG; Busam KJ
Am J Surg Pathol; 2001 Jun; 25(6):782-7. PubMed ID: 11395556
[TBL] [Abstract][Full Text] [Related]
6. A103: An anti-melan-a monoclonal antibody for the detection of malignant melanoma in paraffin-embedded tissues.
Jungbluth AA; Busam KJ; Gerald WL; Stockert E; Coplan KA; Iversen K; MacGregor DP; Old LJ; Chen YT
Am J Surg Pathol; 1998 May; 22(5):595-602. PubMed ID: 9591730
[TBL] [Abstract][Full Text] [Related]
7. High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma.
de Vries TJ; Trancikova D; Ruiter DJ; van Muijen GN
Br J Cancer; 1998 Nov; 78(9):1156-61. PubMed ID: 9820172
[TBL] [Abstract][Full Text] [Related]
8. Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy.
Trefzer U; Hofmann M; Reinke S; Guo YJ; Audring H; Spagnoli G; Sterry W
Melanoma Res; 2006 Apr; 16(2):137-45. PubMed ID: 16567969
[TBL] [Abstract][Full Text] [Related]
9. Improved immunohistochemical evaluation of micrometastases in sentinel lymph nodes of cutaneous melanoma with 'MCW melanoma cocktail'--a mixture of monoclonal antibodies to MART-1, Melan-A, and tyrosinase.
Shidham VB; Qi D; Rao RN; Acker SM; Chang CC; Kampalath B; Dawson G; Machhi JK; Komorowski RA
BMC Cancer; 2003 May; 3():15. PubMed ID: 12735792
[TBL] [Abstract][Full Text] [Related]
10. The monoclonal antibody SM5-1 recognizes a fibronectin variant which is widely expressed in melanoma.
Trefzer U; Chen Y; Herberth G; Hofmann MA; Kiecker F; Guo Y; Sterry W
BMC Cancer; 2006 Jan; 6():8. PubMed ID: 16405722
[TBL] [Abstract][Full Text] [Related]
11. Molecular detection of MART-1, tyrosinase and MIA in peripheral blood, lymph nodes and metastatic sites of stage III/IV melanoma patients.
Enk CD; Lotem M; Gimon Z; Hochberg M
Melanoma Res; 2004 Oct; 14(5):361-5. PubMed ID: 15457091
[TBL] [Abstract][Full Text] [Related]
12. HMB-45, S-100, NK1/C3, and MART-1 in metastatic melanoma.
Zubovits J; Buzney E; Yu L; Duncan LM
Hum Pathol; 2004 Feb; 35(2):217-23. PubMed ID: 14991540
[TBL] [Abstract][Full Text] [Related]
13. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma.
Jäger E; Ringhoffer M; Altmannsberger M; Arand M; Karbach J; Jäger D; Oesch F; Knuth A
Int J Cancer; 1997 Apr; 71(2):142-7. PubMed ID: 9139833
[TBL] [Abstract][Full Text] [Related]
14. Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes.
Goto Y; Ferrone S; Arigami T; Kitago M; Tanemura A; Sunami E; Nguyen SL; Turner RR; Morton DL; Hoon DS
Clin Cancer Res; 2008 Jun; 14(11):3401-7. PubMed ID: 18519770
[TBL] [Abstract][Full Text] [Related]
15. A metastatic melanoma with an unusual immunophenotypic profile.
Gao Z; Stanek A; Chen S
Am J Dermatopathol; 2007 Apr; 29(2):169-71. PubMed ID: 17414440
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
de Vries TJ; Fourkour A; Wobbes T; Verkroost G; Ruiter DJ; van Muijen GN
Cancer Res; 1997 Aug; 57(15):3223-9. PubMed ID: 9242453
[TBL] [Abstract][Full Text] [Related]
17. T311--an anti-tyrosinase monoclonal antibody for the detection of melanocytic lesions in paraffin embedded tissues.
Jungbluth AA; Iversen K; Coplan K; Kolb D; Stockert E; Chen YT; Old LJ; Busam K
Pathol Res Pract; 2000; 196(4):235-42. PubMed ID: 10782467
[TBL] [Abstract][Full Text] [Related]
18. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
[TBL] [Abstract][Full Text] [Related]
19. Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma.
Orchard GE
Histochem J; 2000 Aug; 32(8):475-81. PubMed ID: 11095072
[TBL] [Abstract][Full Text] [Related]
20. Expression of melanocyte differentiation antigens and ki-67 in nodal nevi and comparison of ki-67 expression with metastatic melanoma.
Lohmann CM; Iversen K; Jungbluth AA; Berwick M; Busam KJ
Am J Surg Pathol; 2002 Oct; 26(10):1351-7. PubMed ID: 12360050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]